(NASDAQ: BIOA) Bioage Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 18.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.57%.
Bioage Labs's earnings in 2025 is N/A.On average, 2 Wall Street analysts forecast BIOA's earnings for 2025 to be -$69,725,795, with the lowest BIOA earnings forecast at -$93,206,719, and the highest BIOA earnings forecast at -$46,244,872. On average, 2 Wall Street analysts forecast BIOA's earnings for 2026 to be -$83,169,072, with the lowest BIOA earnings forecast at -$105,395,290, and the highest BIOA earnings forecast at -$60,942,855.
In 2027, BIOA is forecast to generate -$62,735,292 in earnings, with the lowest earnings forecast at -$62,735,292 and the highest earnings forecast at -$62,735,292.